Phase II study of tiazofurin in gliomas in adults - A National Cancer Institute of Canada study
Journal of Neuro-Oncology, ISSN: 0167-594X, Vol: 15, Issue: 2, Page: 175-179
1993
- 4Citations
- 5Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations4
- Citation Indexes4
- CrossRef3
- Captures5
- Readers5
Article Description
The National Cancer Institute of Canada conducted a Phase II study of tiazofurin 1100 to 1375 mg/m IV daily x 5 days in adults with grade 2, 3, and 4 gliomas. No responses were seen. Five of sixteen evaluable patients had stable disease for 38 to 147 days (median, 75 days). Treatment was generally well tolerated, and hence the dose was escalated from 1100mg/m/day to 1375 mg/m/day after the first twelve patients were entered. Treatment-induced hypertension requiring pharmacological intervention was seen in four patients. Gastrointestinal toxicity was generally mild. Treatment-related headache was seen in thirteen patients, and drowsiness or weakness was seen in seven patients. In summary, tiazofurin on this dose schedule does not have major activity against grade 2, 3, and 4 gliomas. © 1993 Kluwer Academic Publishers.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0027156493&origin=inward; http://dx.doi.org/10.1007/bf01053938; http://www.ncbi.nlm.nih.gov/pubmed/8389819; http://link.springer.com/10.1007/BF01053938; http://www.springerlink.com/index/pdf/10.1007/BF01053938; https://dx.doi.org/10.1007/bf01053938; https://link.springer.com/article/10.1007/BF01053938; http://www.springerlink.com/index/10.1007/BF01053938
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know